debridement; however the AOSD remains stable, with oral prednisolone weaned to 40mg daily and subcutaneous anakinra 100mg daily. Discussion: Our patient fulfilled Yamaguchi classification criteria for AOSD with three major criteria (leucocytosis, rash, arthralgia) and four minor criteria (sore throat, lymphadenopathy, hepatomegaly and negative ANA and RF). AOSD is an uncommon condition, with annual incidence estimated to be less than 1 case per 100,000 people. Cardiopulmonary disease can be observed in up to 40 percent of patients with AOSD including pericarditis and pleural effusions, with the more serious manifestations of myocarditis and acute respiratory distress syndrome (ARDS) being described as rare. Whilst myocarditis hasbeen reported to have aprevalenceof around 7% in AOSD, a recent systematic review looking at severe organ manifestations of AOSD (79 cases from 62 publications reviewed) found that 23% of studied cases had cardiac complications, with 15% having myocarditis and 6% having cardiogenic shock associated with this. 20% of cases had multi-organ failure. Organ complications mostly occurred at diagnosis (78% of cases studied). Another pooled case series reviewing myocarditis in AOSD found that myocarditis occurred early in the disease course with 80% occurring in the first year, with 54% having myocarditis at the onset of disease. When AOSD patients with myocarditis were compared to a control group of AOSD without myocarditis, clinical features such as fever, rash and sore throat were similar in both groups; however, arthritis was less frequent in the myocarditis group (25% versus 42%) and total WCC was higher. Interestingly there was no significant difference in serum ferritin levels between these two groups. In all, 50% of cases in both groups required disease modifying treatment beyond corticosteroid therapy. Similarly, a review looking at life-threatening organ complications in AOSD demonstrated that 50% of these cases also required second-line therapies including IVIg or anakinra; however these patients had lower ferritin levels and less severe disease overall. Key learning points: Literature so far suggests the keysevere manifestations of AOSD leading to intensive care admission are cardiogenic failure secondary to myocarditis or cardiogenic shock, non-cardiogenic shock, respiratory failure from ARDS or pleural effusion and haematological complications including macrophage activation syndrome and disseminated intravascular coagulation. Treatment included corticosteroids, IVIg, cyclosporin, etoposide and anakinra, with an efficacy rate of 64% for steroids alone, 41%for IVIg and 89% for IL1-Ra anakinra. We have described a case of AOSD complicated by myocarditis and multi-organ failure, which occurred early in the disease course. Despite these life-threatening complications, our patient responded well to combination treatment with corticosteroids, IVIg and anakinra. Published cases suggest that myocarditis remains an uncommon manifestation of AOSD, but tends to occur early in the course of the disease and can be further complicated by cardiogenic shock, as in our patient. At least half of AOSD patients with myocarditis and/or MOF require further therapies suchas IVIg orAnakinra inaddition tocorticosteroids. Due toits heterogeneous presentation, it is important that general medical physicians, cardiologists and intensive care physicians as well as rheumatologists be aware of the condition and the potential for rapid deterioration. Further study is required to identify which patients with AOSD are at higher risk of developing life-threatening complications associated with this condition. Conflict of interest: The authors declare no conflicts of interest.
AN AUTOINFLAMMATORY SYNDROME RESEMBLING CASTLEMAN'S DISEASE WITH EXCELLENT RESPONSE TO IL-6 BLOCKADE
Mithun Chakravorty 1 , and Rengi Mathew 1 1 Rheumatology Department, Chesterfield Royal Hospital, Chesterfield, United Kingdom Introduction: Autoinflammatory diseases are an emerging group, characterised by recurrent inflammatory episodes due to dysregulated innate immunity. Common features include fevers, rash, arthralgia, lymphadenopathy and systemic symptoms. Castleman's disease is a rare lymphoproliferative disease, associated with the overproduction of interleukin-6 (IL-6). Its two main variants: unicentric and multicentric differ in aetiology and clinical outcomes. The cytokine storm driven by IL-6 canmimicautoinflammatory disease. We present the case of an acquired autoinflammatory syndrome in a 33year-old male with the clinical phenotype of Castleman's but no culprit lymph node detected radiologically. Symptoms dramatically improved with yocilizumab, an IL-6blocker.
Case description: A 33-year-old Caucasian man was referred to rheumatology at his local District General Hospital with flitting joint pains, fevers, night sweats and weight loss for eighteen months. He had associated fatigue, myalgia, sore throat and an intermittent maculopapular rash. There were no specific symptoms of infection, malignancy or underlying connective tissue disease. No risk factors for blood-borne viruses were identified. Past medical history included hearing difficulties in childhood, and maternal family history of Crohn's disease. Currently he was unemployed, having previously worked in a concrete factory.Therewas a 30 pack-year smoking history with moderate alcohol intake. Physical examination revealed a faint maculopapular rash over his right forearm but was otherwise normal. Full blood count showed an improved microcytic anaemia with recent haemoglobin 132 g/L, raised white cell count up to 33 x 10 9 /L (predominant neutrophilia) and mild thrombocytosis up to 480 x 10 9 /L. Inflammatory were persistently elevated with CRP 124 mg/L and ESR 67 mm/hr. Renal, liver and thyroid functions were all normal as well as creatine kinase.Iron studies suggested iron-deficiency with negative anti-endomysial antibodies. Serum ferritin peaked at 1028 during mg/ L during flares, with normal triglycerides. A full autoimmune screen was negative. Immunoglobulins showed a polyclonal rise only. HIV and Hepatitis screens were negative. CT chest, abdomen and pelvis and subsequent PET-CT scan were unremarkable. A bone marrow biopsy showed reactive changes only. A trial of low-dose prednisolone provided dramatic symptomatic improvement but symptoms flared on weaning to 10mg daily. Both steroid-sparing agents azathioprine and methotrexate were not tolerated. After further investigations by the National Amyloidosis Centre, he was commenced on weekly tocilizumab 162mg subcutaneous injections after a successful individual funding request. This provided an excellent clinical response which has been sustained for over two years. Discussion: This case was difficult given the wide differential diagnoses. It was important to rule out infection, malignancy and autoimmune disease which were commoner causes of recurrent fevers and systemic symptoms. The long duration of symptoms, negative blood cultures and unremarkable CT imaging were against deep-seated infection. He was low risk for tuberculosis, zoonosis and tropical infections. No solid tumours or lymph nodes were seen on imaging but the PET-CT noted non-specific bone marrow changes. Bone marrow biopsy showed increased granulopoiesis without features of malignancy, and JAK-2 mutation was negative. Lactate dehydrogenase was normal with negative haemolysis screen. Upper and lower gastrointestinal endoscopies to investigate hisiron-deficiency anaemia were normal. A full autoimmune screen was normal including anti-nuclear antibody, extractible nuclear antigen, rheumatoid factor, anti-cyclic citrullinated peptide antibody, complement C3 and C4 and anti-double-stranded DNA antibody. As no malignancy was found, prednisolone 40mg daily was trialled with fortnightly tapering. This produced a marked improvement in symptoms and inflammatory markers. However there were frequent flares ontapering the dose. He was therefore referred to the National Amyloidosis Centre at the Royal Free Hospital in London for an expert opinion. A genetic screen was negative for NLPR3 (CAPS gene), LRP12, TRAPS gene and the mevalonate kinasegene. Serum amyloid A (SAA)was veryhigh591 m/l (<10) with CRP 120 mg/L. The clinical picture suggested an acquired autoinflammatory disease, most consistent with Castleman's disease of the solitary plasma celltype. Adult-onset Still's disease wasconsideredbut ferritin levels were not typical. A culprit lymph node is usually seen on imaging but occasionallycanbetoo smalltoidentify.Castleman'srespondsverywellto IL-6blockadeandSAAandCRPnormalisedwithfourdosesoftocilizumab. Duration of treatment is unclear. Interval imaging was planned in case a resectablelymphnodedeveloped. Key learning points: Autoinflammatory diseases are rare but treatable causes of fever syndromes. Extensive investigations are needed to exclude mimics such as infection, malignancy (especially haematological) and autoimmuneconditions. Genetic testing can reveal the diagnosis for monogenic types such as familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Castleman's disease can be caused by a single lymph node (unicentric) or diffuse lymph nodes (multicentric). The unicentric type is less associated with systemic symptoms compared to multicentric, except forits rarer plasmacytosis variant. Consider HIV and human herpes virus-8 infection in the multicentric type. IL-6 blockade is extremely effective in Castleman's but optimum duration of therapy remains unclear. Surgical resection of the solitary lymph node in unicentric Castleman's has a good prognosis. Serum amyloid A can be a useful marker of disease activity in autoinflammatory disease compared with CRP. Conflict of interest: The authors declare no conflicts of interest.
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